CRISPR Therapeutics AG
CRSP: XNAS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$862.00 | Kpsz | Xmvmndsq |
CRISPR Therapeutics’ Pipeline Progress Tracks Expectations; $119 FVE, Shares Very Undervalued
CRISPR Therapeutics posted third-quarter results in line with our expectations, and its pipeline candidates are continuing to progress in development. We maintain our fair value estimate of $119 per share and view the stock as very undervalued, currently trading in 5-star territory. As a clinical-stage biotech company, CRISPR Therapeutics provides long-term investors with pure play exposure to novel gene editing technology to treat severe genetic diseases.